Case Report

Clitoromegaly, Vulvovaginal Hemangioma Mimicking Pelvic Organ Prolapse, and Heavy Menstrual Bleeding: Gynecologic Manifestations of Klippel-Trénaunay Syndrome

Gina Nam 1,†, Sa Ra Lee 2,* and SeungA Choi 2,†

1 Department of Obstetrics and Gynecology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, 102, Heukseok-ro, Dongjak-gu, Seoul 06973, Korea; ginanam@caumc.or.kr
2 Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea; chsa1002@gmail.com
* Correspondence: leesr@amc.seoul.kr; Tel.: +82-2-3010-3648
† Gina Nam and SeungA Choi contributed equally and share the primary authorship.

Abstract: Klippel-Trénaunay Syndrome (KTS) is a genetic vascular malformation involving the capillary, lymphatic, and venous channels. Prenatal sonographic diagnosis of KTS with an enlarged fetal limb is well-known; however, postnatal gynecologic manifestations are rarely reported. KTS can cause clitoromegaly, vulvovaginal hemangioma, and heavy menstrual bleeding. Somatic mosaicism of the PIK3CA gene is considered as responsible for KTS but reports based on whole-genome sequencing are limited. A 31-year-old woman with KTS presented with bulging of the clitoris and vagina. Analysis of whole-genome sequencing variant data revealed that gene ontology terms related to development and differentiation such as ‘skeletal system morphogenesis’, ‘embryonic morphogenesis’, and ‘sensory organ development’ were nominally significant in non-coding regions. Variants in non-coding genes may be responsible for this phenotype.

Keywords: Klippel-Trénaunay syndrome; clitoris; hemangioma; pelvic organ prolapse; heavy menstrual bleeding; whole genome sequencing

1. Introduction

Klippel-Trénaunay syndrome (KTS) is a rare vascular malformation with an incidence of 1/30,000 live births [1]. It is defined as a triad of the following: (1) capillary lymphangiovenous malformations, which are typically presented as port-wine stains, a type of cutaneous capillary malformation or superficial vascular blebs, and a type of lymphatic malformation; (2) soft tissue and bone hypertrophy, beginning in infancy and most often only affecting one leg; and (3) varicose veins or venous malformation, mostly with persistent lateral embryologic veins [2]. KTS can be diagnosed when two of the three features are observed. Genitourinary involvement and postnatal gynecologic problems associated with KTS are rarely reported. Herein, we report the first case of clitoral and vaginal manifestations of KTS mimicking those of clitoromegaly and pelvic organ prolapse. Accompanying heavy menstrual bleeding (HMB) was well-controlled with non-steroidal anti-inflammatory drugs (NSAIDs). KTS is a sporadic congenital disorder resulting from somatic mutations of the phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) gene, which is involved in cell growth and proliferation [3]. We also performed whole-genome sequencing (WGS) to detect novel KTS variants responsible for the vascular phenotype.

2. Case

A 31-year-old woman with known KTS presented with a progressive bulging of the clitoris and vagina associated with aggravating HMB. A physical examination revealed
hemihypertrophy of the right lower limb, hemangioma of the right vulva, and ambiguous genitalia with an elongated clitoral hood approximately 4 cm in length (Figure 1A). An enlarged, 2.0 × 1.8-cm² whitish globular glans of the clitoris and a purplish bulging anterior vaginal wall mimicking pelvic organ prolapse were also observed (Figure 1B). Typical port-wine nevus, capillary malformation, and bullous plaques, pathologically proven lymphatic malformations, were detected on the buttock (Figure 1C). Sonography and magnetic resonance imaging (MRI) showed a typical sponge-like shadow in the vulva, bladder, and rectum on T1 weighted images and an extensive cavernous hemangioma in the pelvis pushed the uterine fundus up to the above the umbilicus (Figure 1D–G). The upper margin of the uterine fundus was observed around the third lumbar spine vertebra. The HMB was well-controlled with oral aceclofenac, an NSAID, during menstrual periods.

Figure 1. (A) Hemihypertrophy of the right lower limb, hemangioma of the right vulva, and ambiguous genitalia with an elongated clitoral hood, approximately 4 cm in length (shown in the dotted circle). (B) An enlarged, 2.0 × 1.8-cm² whitish globular clitoris glans and a purplish bulging anterior vaginal wall. (C) Typical port-wine nevus (dotted circle) and bullous plaques (arrows) on the buttock. (D) The upper margin of the uterine fundus (U) was noted around the abdominal aorta (A) and inferior vena cava (IVC) on sonography. (E) A typical sponge-like shadow consisting of a mass-like lesion without Doppler flow in the bladder (Bl) was observed by sonography. (F) Hemihypertrophy of the right lower limb and hemangioma of the right vulva with an enlarged clitoris viewed with MRI. (G) A typical sponge-like shadow in the bladder (Bl) and rectum (dotted circle) viewed in T1-weighted images, and an extensive cavernous hemangioma in the pelvis pushing the uterine fundus (U) up to above the umbilicus (arrowhead) shown on MRI. * (internal cervical os); ** (external cervical os).

A genetic analysis by WGS was performed using peripheral blood DNA on an Illumina HiSeq X system (Illumina, San Diego, CA, USA). The average read length was 150 base pairs. DNA was prepared according to the Illumina DNA sample preparation guide. For alignment and genotyping, an Isaac aligner (Illumina, San Diego, CA, USA) and a variant caller (Illumina, San Diego, CA, USA) were applied. The hg19 reference genome from the University of California Santa Cruz (UCSC) genome database was used.

2.1. Identification of Mutation Variants Associated with KTS

To detect variants responsible for the development of KTS, we used the wANNOVAR (http://wannovar.wglab.org/ (accessed on 9 February 2021)) (Wang Genomics Lab,
Philadelphia, PA, USA). The wANNOVAR is a web version of the ANNOVAR (ANNo-

1ation of VARiation) database used for the interpretation and prioritization of variants in a
genome. The variants include single-nucleotide variants, insertions, deletions, and copy
number variants. After annotation, the variants can be filtered according to the criteria
relevant to the disease model, particularly for Mendelian diseases. Based on previous
research, we set the following filtering criteria: (1) variants confined to the exonic region,
(2) elimination of synonymous and non-frameshift variants, (3) filtering out of variants
present in the 1000 Genomes Project, ExAC, ESP6500, and gnomAD databases, (4) removal
of variants in dbSNP version 130, (5) Combined Annotation-Dependent Depletion phred
(CADD-phred) score >10. After identifying the disease variants, we applied the associated
genes to the DAVID web tool (http://david.abcc.ncifcrf.gov (accessed on 9 February 2021))
for a functional enrichment analysis of genes with a variety of biological parameters, such
as gene ontology (GO), pathways, disease genes, and transcription factor-binding sites.
The enrichment test is a statistical analysis that tests the over-representation of genes associated
with a functional category in a set of genes. The enrichment test provides information
on the functional implications of a set of genes using biological knowledge and statistical
testing. We used the enrichment test to determine whether the biological implication of the
variants was consistent with the pathophysiology of KTS.

2.2. WGS Results

In total, 987,625,204 reads were generated from the processed DNA sample. The
proportion of reads with a quality score greater than 20 (>Q20) was 95.64%. The mean
depth of the mapped reads was 44.3, and 98.7% of reads had ≥5× coverage.

2.3. Results of Annotation Using wANNOVAR and DAVID

Among the 3.9 million single-nucleotide variants (number of single-nucleotide vari-
ants = 3,972,786) genotyped by WGS, there were 22,026 variants in exonic regions. We
first annotated the exonic variants and applied an enrichment analysis. We excluded
synonymous (n = 11,004) and non-frameshift substitution (n = 142) variants from further
analysis. The remaining variants were filtered using our criteria, and there were 34 variants
in the results (Supplementary Material Table S1). There were 33 non-synonymous and one
stop-gain variants. These variants were mapped to 34 genes and used for an enrichment
analysis. An enrichment analysis showed that the ‘cell fate commitment’ biological process
GO term was significant, indicating that associated genes were over-represented among the
variants (Supplementary Material Table S2). The nominal significance of the enrichment
test with this GO term was very strong (p = 3.12 × 10⁻⁵), and the multiple testing correction
by the Benjamini-Hochberg method was also significant (p = 0.03). The definition of the ‘cell
fate commitment’ term is the commitment of cells to specific cell fates and their capacity
to differentiate into specific cell types (https://www.ebi.ac.uk/QuickGO/term/GO:0045165
(accessed on 9 February 2021)). Table 1 shows the variants that are members of the ‘cell
fate commitment’ GO term.

Table 1. Members of the gene ontology (GO) term “cell fate commitment”.

| Chr | Pos   | Ref | Alt | RefGene    | Amino Acid Change                                      | CADD_Phred |
|-----|-------|-----|-----|------------|--------------------------------------------------------|------------|
| 7   | 39247040 | C   | T   | POU6F2     | NM_001166018:exon5:c.C332T:p.P111L, NM_001166018:exon5:c.C332T:p.P111L | 28.7       |
| 11  | 78498012 | C   | T   | TENM4      | NM_001098816:exon16:c.G2296A:p.E766K                    | 24.1       |
| 17  | 7749575 | G   | C   | KDM6B      | NM_001080424:exon6:c.G416C:p.S139T, NM_001080424:exon6:c.G416C:p.S139T | 22.9       |
| 19  | 1469116  | G   | C   | APC2       | NM_001351723:exon14:c.G5813C:p.R1938P, NM_001351723:exon14:c.G5813C:p.R1938P | 23.5       |
| 21  | 34400126 | C   | G   | OLIG2      | NM_0058066:exon2:c.C956G:p.T195S                         | 13.52      |
| 22  | 19754382 | C   | G   | TBX1       | NM_0080467:exon9:c.C1480G:p.F494A                         | 26.4       |

GO, Gene Ontology; Chr, Chromosome; Pos, Position; Ref, Reference allele; Alt, Alternative allele; RefGene, Reference gene; CADD_phred, Combined Annotation-Dependent Depletion_phred.
We also applied the same analysis to non-exonic variants of whole genomes, except for those in intronic and intergenic regions. The contribution of variants in the intronic and intergenic regions has not been widely reported compared with exonic regions in the analysis of genetic diseases, and we excluded variants from these regions. Thereafter, we removed the CADD score criterion because this system has limited clinical validity for variants in the non-coding region. After filtering, 362 variants and 372 genes were mapped and used as input gene lists for enrichment analysis (Supplementary Material Table S3). An enrichment analysis revealed no significant GO terms. Whereas the nominal \( p \) values showed significance, \( p \) values based on multiple testing corrections were not significant (Supplementary Material Table S4). However, the nominally significant GO terms were found to be related to development and differentiation terms, such as ‘skeletal system morphogenesis’, ‘embryonic morphogenesis’, and ‘sensory organ development’.

3. Discussion

KTS is a rare overgrowth disorder that is genetically caused by a somatic mutation and is typically not inherited. In terms of genes, the most commonly involved mutations are in \( \text{PIK3CA} \) [4]. \( \text{PIK3CA} \) encodes the catalytic subunit of the enzyme phosphatidylinositol 3-kinase, which plays important roles in multiple signaling pathways, such as the vascular endothelial growth factor, fibroblast growth factor, and insulin-like growth factor pathways [5]. These genetic changes are responsible for the development of tissues in the body, resulting in overgrowth and explaining the hyperplasia seen in KTS.

A \( \text{PIK3CA} \) single gene test was reported for KTS [4,6] for determining a targeted molecular diagnosis through a biopsy of affected tissues [3,7]. Luks et al. found that \( \text{PIK3CA} \) mutations were present at low frequencies (<10%) in many affected tissue samples [6]. Due to the inaccessibility or invasiveness of a solid biopsy, next-generation sequencing of cell-free DNA has recently been used as a non-invasive diagnostic tool for KTS [3]. In this study, we performed WGS to explain the difficulty in enriching only \( \text{PIK3CA} \) mutations and affected tissue from biopsies. We detected no mutations in \( \text{PIK3CA} \) by WGS. The use of the GO database maximized the information available for the gene enrichment analysis [8]. The results of the enrichment test with GO terms in exonic regions indicated that the detected variants were causal alleles because the cell fate commitment GO term is related to cellular differentiation, and KTS has features of dysregulated cellular differentiation and development. The significant GO terms were also found to be related to development and differentiation terms in intronic and intergenic regions. These results indicated that variants in non-coding regions were also responsible for genetic diseases, although more evidence that directly links the non-coding variants to phenotypic expression is required to confirm the pathologic non-coding variants.

In terms of clinical manifestations, most reports have focused on bone and soft tissue involvement. Genitourinary involvement was reported in 9–30% of cases, and vulvar hemangioma is the most common gynecologic manifestation [1,9]. A six-year-old female patient with KTS with bloody vaginal discharge and swelling in the left inguinal region was reported [10]. One report showed that five of 218 patients had severe HMB, and all had vascular abnormalities of the uterus and upper vagina on MRI [1]. In this case, the patient also complained of aggravating HMB with the progressive bulging of the clitoris and anterior vaginal wall mimicking pelvic organ prolapse.

A report described that HMB associated with KTS was controlled by luteinizing hormone-releasing hormone analogues and progestogens [11]. However, another patient was unresponsive to a gonadotropin-releasing hormone receptor agonist with add-back therapy and bilateral uterine artery embolization; thus, she underwent a hysterectomy for definitive surgical therapy [12]. Clinicians should also consider the risk of thrombosis, as well as bleeding, in the management of KTS. Jacob et al. reported that nine of 252 patients (4%) with KTS had a pulmonary embolism associated with pelvic surgical procedures, oral contraceptives, pregnancy, and invasive procedures [7]. Therefore, the use of oral contraceptives or antifibrinolytic agents should be avoided in patients with
KTS for controlling HMB, and NSAIDs can be the treatment choice, as in the current case. The endometrium with HMB has higher levels of prostaglandins compared with that of normal menstruation [13]. Prostaglandins are vasodilatory agents known to increase cyclooxygenase enzyme expression [14], and thus the administration of cyclooxygenase enzyme inhibitors has been used as therapy for HMB. NSAIDs inhibit cyclooxygenase enzyme systems and reduce menstrual blood loss by 25–35% in around three-quarters of women with HMB [15].

Cutaneous capillary malformation and lymphatic malformation can be also complicated by bleeding and infection [7]. Treatment must be conservative when managing coexisting cellulitis or lymphangitis with antibiotics and compression therapy, as invasive procedures may cause serious bleeding. Husmann et al. reported that patients with cutaneous abnormalities over the trunk or perineum are three-fold more likely to have visceral vascular anomalies [1]. This suggests that port-wine stains of the perineum are predictive of visceral genitourinary involvement. A radiologic evaluation is required to screen patients with KTS for visceral vascular malformations, particularly before major procedures or operations. In our case, sonography and MRI revealed an extensive cavernous hemangioma in the bladder and rectum. Therefore, physicians must be cautious when performing invasive diagnostic exams, such as cystoscopy or recto-sigmoidoscopy, in which malformed vasculature has been noted on imaging to ensure that bleeding from the malformed vasculature is not encountered.

4. Conclusions

This is the first report of the involvement of clitoral and vaginal manifestations of KTS mimicking pelvic organ prolapse. The need for a postnatal gynecologic evaluation of the abdominopelvic extension of KTS can be determined, and the risk of bleeding, as well as thrombosis, should be considered in the management of KTS. Further studies are needed to determine the genetic causes of KTS.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/medicina57040366/s1, Table S1: The results of ANNOVAR annotation in exonic regions, Table S2: Result of DAVID functional annotation, Table S3: Result of ANNOVAR annotation in non-exonic regions, Table S4. Result of Gene Ontology annotation with biological function (BP) terms.

Author Contributions: Conceptualization, S.R.L.; formal analysis, G.N.; investigation, S.C.; resources, S.R.L.; data curation, S.C.; writing—original draft preparation, G.N.; writing—review and editing, S.R.L.; visualization, S.R.L.; supervision, S.R.L.; project administration, S.R.L. All authors have read and agreed to the published version of the manuscript.

Funding: The work was funded by the Institute for National IT Industry Promotion Agency (NIPA) grant funded by the Korean government (MSIT; No. A0602-19-1032, Intelligent surgical guide system & service from surgery video data analytics).

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and was approved by the Institutional Review Board for Human Research of Asan Medical Center (approval No. 2020-0728, approval date: 7 May 2020).

Informed Consent Statement: Informed consent was obtained from the participant included in the study for the publication of their data.

Data Availability Statement: The data presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy and ethical concerns.

Conflicts of Interest: The author declares no conflict of interest.

References
1. Husmann, D.; Rathburn, S.; Driscoll, D. Klippel-Trenaunay syndrome: Incidence and treatment of genitourinary sequelae. J. Urol. 2007, 177, 1244–1249. [CrossRef] [PubMed]
2. Patel, N.; Swana, H.; Johnson, C. Genitourinary involvement in pediatric patients with Klippel-Trenaunay syndrome. Clin. Imaging 2020, 67, 117–120. [CrossRef] [PubMed]
3. Palmieri, M.; Pinto, A.M.; di Blasio, L.; Curri, A.; Monica, V.; Sarno, L.D.; Doddat, G.; Baldassarri, M.; Frullanti, E.; Giliberti, A. A pilot study of next generation sequencing–liquid biopsy on cell-free DNA as a novel non-invasive diagnostic tool for Klippel–Trenaunay syndrome. **Vascular 2020**, 1708538120936421. [CrossRef]

4. Vahidnezhad, H.; Youssefian, L.; Utttto, J. Klippel–Trenaunay syndrome belongs to the PIK3CA-related overgrowth spectrum (PROS). **Exp. Dermatol. 2016**, 25, 17–19. [CrossRef] [PubMed]

5. Vanhaesebroeck, B.; Stephens, L.; Hawkins, P. PI3K signalling: The path to discovery and understanding. **Nat. Rev. Mol. Cell Biol. 2012**, 13, 195–203. [CrossRef] [PubMed]

6. Luks, V.L.; Kamitaki, N.; Vivero, M.P.; Uller, W.; Rab, R.; Bovée, J.V.; Rialon, K.L.; Guevara, C.J.; Alomari, A.I.; Greene, A.K. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. **J. Pediatr. 2015**, 166, 1048–1054.e5. [CrossRef] [PubMed]

7. Jacob, A.G.; Driscoll, D.J.; Shaughnessy, W.J.; Stanson, A.W.; Clay, R.P.; Gloviczki, P. Klippel-Trenaunay syndrome: Spectrum and management. **Mayo Clinic Proceedings. 1998**, 73, 28–36. [CrossRef]

8. Alterovitz, G.; Xiang, M.; Mohan, M.; Ramoni, M.F. GO PaD: The gene ontology partition database. **Nucleic Acids Res. 2007**, 35, D322–D327. [CrossRef] [PubMed]

9. Ahmed, I.; Aslam, M.; Bin Mahfooz, A.; Hanash, K. Genitourinary manifestations of Klippel–Trenaunay syndrome: Report of two cases managed with systemic α-interferon. **Scand. J. Urol. Nephrol. 2005**, 39, 523–526. [CrossRef] [PubMed]

10. Turkmen, M.; Kavukçu, S.; Çakmakci, H.; Soylu, A.; Aktan, S.; Çağan, Y. A girl of Klippel-Trenaunay Weber syndrome coexistence of recurrent bloody vaginal discharge. **Int. Urol. Nephrol. 2010**, 42, 575–578. [CrossRef] [PubMed]

11. Ovando, E. Klippel-Trenaunay-Weber syndrome with vesical and uterine involvement treated by endoscopic and endovascular routes. **Medicina 2020**, 80, 84–86.

12. Milman, T.; Murji, A.; Papillon-Smith, J. Abnormal uterine bleeding in a patient with Klippel-Trenaunay syndrome. **J. Minim. Invasive Gynecol. 2019**, 26, 791–793. [CrossRef] [PubMed]

13. Willman, E.A.; Collins, W.; Clayton, S. Studies in the involvement of prostaglandins in uterine symptomatology and pathology. **BJOG 1976**, 83, 337–341. [CrossRef] [PubMed]

14. Maldve, R.E.; Kim, Y.; Muga, S.J.; Fischer, S.M. Prostaglandin E2 regulation of cyclooxygenase expression in keratinocytes is mediated via cyclic nucleotide-linked prostaglandin receptors. **J. Lipid Res. 2000**, 41, 873–881. [CrossRef]

15. Cameron, I. Medical management of menorrhagia. **Curr. Obstet. Gynaecol. 1992**, 2, 136–140. [CrossRef]